TY - JOUR
T1 - Probiotics in irritable bowel syndrome and inflammatory bowel disease
T2 - review of mechanisms and effectiveness
AU - So, Daniel
AU - Quigley, Eamonn M.M.
AU - Whelan, Kevin
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Purpose of reviewThe gastrointestinal (GI) microbiome has been implicated in the pathogenesis of inflammatory bowel disease (IBD) and has been linked with irritable bowel syndrome (IBS). The aim of this article is to critically review the emerging evidence for the mechanisms and effectiveness of probiotics in the management of these conditions.Recent findingsThe GI microbiome is strongly influenced by ageing, diet and disease. Probiotics may confer health effects to the host by modulating the metabolic activities of the microbiome to propagate anti-inflammatory effects and reinforce the intestinal barrier, and are considered to be safe to use. Many short-term studies have demonstrated the effectiveness of probiotics overall in IBS, with meta-analyses demonstrating efficacy across specific strains albeit with relatively small effect sizes. Within IBD, some probiotics appear to offer clinical benefit in ulcerative colitis but strain-specific effects are unclear. Evidence for the use of probiotics in Crohn's disease remains limited.SummaryProbiotics offer considerable potential for the management of IBS and possibly in IBD, however, any benefits conferred appear to be strain-specific. High quality trials of specific probiotics in IBS and IBD, as well as laboratory investigations of their mechanism of action, are required in order to fully understand their potential therapeutic value.
AB - Purpose of reviewThe gastrointestinal (GI) microbiome has been implicated in the pathogenesis of inflammatory bowel disease (IBD) and has been linked with irritable bowel syndrome (IBS). The aim of this article is to critically review the emerging evidence for the mechanisms and effectiveness of probiotics in the management of these conditions.Recent findingsThe GI microbiome is strongly influenced by ageing, diet and disease. Probiotics may confer health effects to the host by modulating the metabolic activities of the microbiome to propagate anti-inflammatory effects and reinforce the intestinal barrier, and are considered to be safe to use. Many short-term studies have demonstrated the effectiveness of probiotics overall in IBS, with meta-analyses demonstrating efficacy across specific strains albeit with relatively small effect sizes. Within IBD, some probiotics appear to offer clinical benefit in ulcerative colitis but strain-specific effects are unclear. Evidence for the use of probiotics in Crohn's disease remains limited.SummaryProbiotics offer considerable potential for the management of IBS and possibly in IBD, however, any benefits conferred appear to be strain-specific. High quality trials of specific probiotics in IBS and IBD, as well as laboratory investigations of their mechanism of action, are required in order to fully understand their potential therapeutic value.
KW - inflammatory bowel disease
KW - irritable bowel syndrome
KW - microbiome
KW - probiotics
UR - http://www.scopus.com/inward/record.url?scp=85148681943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148681943&partnerID=8YFLogxK
U2 - 10.1097/MOG.0000000000000902
DO - 10.1097/MOG.0000000000000902
M3 - Review article
C2 - 36821458
AN - SCOPUS:85148681943
VL - 39
SP - 103
EP - 109
JO - Current opinion in gastroenterology
JF - Current opinion in gastroenterology
SN - 0267-1379
IS - 2
ER -